Skip to content

Home
About
- Management Team
- Board of Directors
Pipeline
News and Events
Partnerships
Careers
Contact

Search for:

Parion Sciences

bout

pipeline

newsslide

Home

Parion Sciences

Parion Sciences is a development stage company dedicated to research, development, and commercialization of therapies to restore the innate mucosal surface defense of the lung.

Parion’s science driven technologies target respiratory diseases that are caused by defective mucosal host defense

PIPELINE

ENAC PULMONARY

tPAD

Mucolytic Agents

Research Programs

CLINICAL TRIALS

ABOUT PARION

ABOUT US
learn more…

PARTNERSHIPS
learn more…

CAREERS
learn more…

CONTACT US
learn more…

RECENT POSTS

Parion Sciences Announces Publication of Phase 2 CLEAN-PCD Study in The Lancet Respiratory Medicine
Parion Sciences Receives Positive Opinion from EMA Paediatric Committee on the Paediatric Investigation Plan for Idrevloride Inhalation Solution for Treatment of Primary Ciliary Dyskinesia
Parion Sciences P‐1037 Inhalation Solution receives Orphan Drug Designation from the EMA for the Treatment of Primary Ciliary Dyskinesia

Search for:

Recent Posts

Parion Sciences Announces Publication of Phase 2 CLEAN-PCD Study in The Lancet Respiratory Medicine
Parion Sciences Receives Positive Opinion from EMA Paediatric Committee on the Paediatric Investigation Plan for Idrevloride Inhalation Solution for Treatment of Primary Ciliary Dyskinesia
Parion Sciences P‐1037 Inhalation Solution receives Orphan Drug Designation from the EMA for the Treatment of Primary Ciliary Dyskinesia
FDA Grants Orphan Drug Designation, Fast Track Designation and Rare Pediatric Disease Designation to Parion Sciences P-1037 Inhalation Solution for the Treatment of Primary Ciliary Dyskinesia
Parion Sciences Reacquires Rights to Epithelial Sodium Channel Inhibitors

Recent Comments

Archives

September 2023
April 2023
November 2020
July 2020
January 2020
October 2019
May 2017
November 2016
October 2016
July 2016
May 2016
January 2016
October 2015
September 2015
June 2015
May 2015
February 2015
November 2014
October 2014
September 2014
June 2014
May 2014
April 2014
November 2013

Categories

News & Event
Uncategorized

Meta

Log in
Entries feed
Comments feed
WordPress.org

Home | About | Pipeline |

Expanded Access |

News & Events | Partnerships | Careers | Contact | FCOI Policy

Copyright © 2025. All Rights Reserved.

Main menu

AcceptParion uses cookies on this website with your consent to analyze traffic and to improve your user experience. For more information, including about the cookies we use and how to control cookies, please see our Privacy Policy. By continuing to surf on our website, you consent to the use of cookies. You can always opt out (e.g. by deleting the cookies), however, you may not be able to use the full functionalities of the website if you do.

Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT